Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.02 per share a year ago.
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector shares plunge after dementia drug fails to slow disease progression
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
Alector, Inc. - Special Call
Alector, Inc. - Special Call Company Participants Katie Hogan - Senior Director of Corporate Communication & Investor Relations Sara Kenkare-Mitra - President and Head of Research & Development Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Thomas Shrader - BTIG, LLC, Research Division Steven Alexopoulos - TD Cowen, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Alec Stranahan - BofA Securities, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Alector's conference call and webcast highlighting its progranulin franchise and Alector Brain Carrier programs.
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Katie Hogan - Senior Director of Corporate Communication & Investor Relations Neil Berkley - Interim CFO & Chief Business Officer Saraswati Kenkare-Mitra - President and Head of Research & Development Conference Call Participants Alec Warren Stranahan - BofA Securities, Research Division Michael H. Riad - Morgan Stanley, Research Division Myles Robert Minter - William Blair & Company L.L.C.
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.4 per share a year ago.
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
